{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:57:20Z","timestamp":1740135440911,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013711","name":"Bayer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>IMPACT-AF is a prospective, randomized, cluster design trial comparing atrial fibrillation (AF) management with a computerized decision support system (CDS) to usual care (control) in the primary care setting of Nova Scotia, Canada. The objective of this analysis was to compare the resource use and costs between CDS and usual care groups.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Case costing data, 12-month self-administered questionnaires, and monthly diaries from IMPACT-AF were used in this analysis. Descriptive statistics were used to compare costs and resource use between groups. All costs are presented in 2021 Canadian dollars and cover the 12-month period of participation in the study.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1,145 patients enrolled in the trial. Case costing data were available for 466 participants (41.1%), 12-month self-administered questionnaire data for 635 participants (56.0%) and monthly diary data for 223 participants (19.7%). Emergency department visits and hospitalizations comprised the most expensive component of AF care. Across all three datasets, there were no statistically significant differences in costs or resource use between CDS and usual care groups.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although there were no significant differences in resource use or costs among CDS and usual care groups in the IMPACT-AF trial, this study provides insight into the methodology and practical challenges of collecting economic data alongside a trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov (registration number: NCT01927367, date of registration: 2013-08-20).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12911-023-02329-7","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T15:03:44Z","timestamp":1697641424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Resource use and cost associated with computerized decision support system and usual care in managing patients with atrial fibrillation: analysis of IMPACT-AF randomized trial data"],"prefix":"10.1186","volume":"23","author":[{"given":"Brittany","family":"Humphries","sequence":"first","affiliation":[]},{"given":"Jafna L","family":"Cox","sequence":"additional","affiliation":[]},{"given":"Ratika","family":"Parkash","sequence":"additional","affiliation":[]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[]},{"given":"Gary A","family":"Foster","sequence":"additional","affiliation":[]},{"given":"James","family":"MacKillop","sequence":"additional","affiliation":[]},{"given":"Joanna","family":"Nemis-White","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Hamilton","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Ciaccia","sequence":"additional","affiliation":[]},{"given":"Shurjeel H","family":"Choudhri","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Kovic","sequence":"additional","affiliation":[]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"2329_CR1","unstructured":"Atrial fibrillation. Heart & Stroke Foundation of Canada. [cited 2021 August 14]. Available from: https:\/\/www.heartandstroke.ca\/heart\/conditions\/atrial-fibrillation."},{"issue":"9","key":"2329_CR2","first-page":"869","volume":"20","author":"KH Humphries","year":"2004","unstructured":"Humphries KH, Jackevicius C, Gong Y, Svensen L, Cox J, Tu JV, et al. Population rates of hospitalization for atrial fibrillation\/flutter in Canada. Can J Cardiol. 2004;20(9):869\u201376.","journal-title":"Can J Cardiol"},{"issue":"2","key":"2329_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cjca.2012.03.023","volume":"29","author":"DJ O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly DJ, Hopkins RB, Healey JS, Dorian P, Sauriol L, Tarride J-E, et al. The Burden of Atrial Fibrillation on the Hospital Sector in Canada. Can J Cardiol. 2013;29(2):229\u201335.","journal-title":"Can J Cardiol"},{"issue":"2","key":"2329_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jval.2011.09.009","volume":"15","author":"WP Wodchis","year":"2012","unstructured":"Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2012;15(2):240\u20138.","journal-title":"Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"issue":"12","key":"2329_CR5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","volume":"36","author":"JG Andrade","year":"2020","unstructured":"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive Guidelines for the management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847\u2013948.","journal-title":"Can J Cardiol"},{"key":"2329_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ahj.2018.04.008","volume":"201","author":"JL Cox","year":"2018","unstructured":"Cox JL, Parkash R, Abidi SS, Thabane L, Xie F, MacKillop J, et al. Optimizing primary care management of atrial fibrillation: the rationale and methods of the Integrated Management Program advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. Am Heart J. 2018;201:149\u201357.","journal-title":"Am Heart J"},{"key":"2329_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ahj.2020.02.019","volume":"224","author":"JL Cox","year":"2020","unstructured":"Cox JL, Parkash R, Foster GA, Xie F, MacKillop JH, Ciaccia A, et al. Integrated Management Program advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): a cluster randomized trial of a computerized clinical decision support tool. Am Heart J. 2020;224:35\u201346.","journal-title":"Am Heart J"},{"issue":"15","key":"2329_CR8","doi-asserted-by":"publisher","first-page":"e019783","DOI":"10.1161\/JAHA.120.019783","volume":"10","author":"B Humphries","year":"2021","unstructured":"Humphries B, Cox JL, Parkash R, Thabane L, Foster GA, MacKillop J, et al. Patient-reported outcomes and patient\u2010reported experience of patients with Atrial Fibrillation in the IMPACT\u2010AF Clinical Trial. J Am Heart Association. 2021;10(15):e019783.","journal-title":"J Am Heart Association"},{"issue":"22","key":"2329_CR9","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1001\/jama.2022.21022","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines for reporting outcomes in Trial Reports: the CONSORT-Outcomes 2022 extension. JAMA. 2022;328(22):2252\u201364.","journal-title":"JAMA"},{"key":"2329_CR10","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332","DOI":"10.1136\/bmj.c332"},{"key":"2329_CR11","unstructured":"NSHA Management Zones. Nova Scotia Department of Health and Wellness. [cited 2021 August 14]. Available from: http:\/\/www.cdha.nshealth.ca\/node\/20735."},{"key":"2329_CR12","unstructured":"Case Costing. Nova Scotia Department of Health and Wellness. [cited 2021 August 14]. Available from: https:\/\/www.cdha.nshealth.ca\/about-us\/case-costing."},{"key":"2329_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhealeco.2014.01.007","volume":"35","author":"G Kjellsson","year":"2014","unstructured":"Kjellsson G, Clarke P, Gerdtham U-G. Forgetting to remember or remembering to forget: a study of the recall period length in health care survey questions. J Health Econ. 2014;35:34\u201346.","journal-title":"J Health Econ"},{"key":"2329_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jclinepi.2018.09.006","volume":"106","author":"J Griffin","year":"2019","unstructured":"Griffin J, Lall R, Bruce J, Withers E, Finnegan S, Lamb SE, et al. Comparison of alternative falls data collection methods in the Prevention of Falls Injury Trial (PreFIT). J Clin Epidemiol. 2019;106:32\u201340.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2329_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","volume":"17","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials \u2013 a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"2329_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s12325-009-0066-x","volume":"26","author":"MH Kim","year":"2009","unstructured":"Kim MH, Lin J, Hussein M, Kreilick C, Battleman D. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009;26(9):847\u201357.","journal-title":"Adv Ther"},{"issue":"8","key":"2329_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jval.2021.03.016","volume":"24","author":"M Laberge","year":"2021","unstructured":"Laberge M, Coulibaly LP, Berthelot S, Borges da Silva R, Guertin JR, Strumpf E, et al. Development and validation of an instrument to measure Health-Related out-of-Pocket costs: the cost for patients Questionnaire. Value in Health. 2021;24(8):1172\u201381.","journal-title":"Value in Health"},{"issue":"7","key":"2329_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0895-4356(99)00177-8","volume":"53","author":"MEJB Goossens","year":"2000","unstructured":"Goossens MEJB, M\u00f6lken MPMHR-v, Vlaeyen JWS, van der Linden SMJP. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000;53(7):688\u201395.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2329_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11205-017-1569-5","volume":"137","author":"S Chatzitheochari","year":"2018","unstructured":"Chatzitheochari S, Fisher K, Gilbert E, Calderwood L, Huskinson T, Cleary A, et al. Using new technologies for time diary data collection: instrument design and data quality findings from a mixed-mode pilot survey. Soc Indicators Res. 2018;137(1):379\u201390.","journal-title":"Soc Indicators Res"},{"key":"2329_CR20","unstructured":"Mogyorosy Z, Smith PC. The main methodological issues in costing health care services - a literature review. York: Centre for Health Economics, University of York; 2005. p. 242. (CHE Research Paper)."},{"issue":"1","key":"2329_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s13063-021-05488-y","volume":"22","author":"JM Nemis-White","year":"2021","unstructured":"Nemis-White JM, Hamilton LM, Shaw S, MacKillop JH, Parkash R, Choudhri SH, et al. Lessons learned from Integrated Management Program advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): a pragmatic clinical trial of computerized decision support in primary care. Trials. 2021;22(1):531.","journal-title":"Trials"},{"issue":"10","key":"2329_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00392-011-0320-5","volume":"100","author":"T Meinertz","year":"2011","unstructured":"Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P, et al. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011;100(10):897\u2013905.","journal-title":"Clin Res Cardiol"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-023-02329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-023-02329-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-023-02329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T19:15:06Z","timestamp":1700334906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-023-02329-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2329"],"URL":"https:\/\/doi.org\/10.1186\/s12911-023-02329-7","relation":{},"ISSN":["1472-6947"],"issn-type":[{"type":"electronic","value":"1472-6947"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with local guidelines and regulations. Ethics approval was provided by the Nova Scotia Health Authority Research Ethics Board. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JC reports grants from Bayer Inc., during the conduct of the study; personal fees from Bayer and Servier, outside the submitted work. RP reports grants from Bayer and Pfizer, during the conduct of the study. JMK reports other fees from Merck Canada, Bayer, and Pfizer, outside the submitted work. AC and SHC are employees of Bayer Inc. JNW reports personal fees from Nova Scotia Health Authority during the conduct of the study. BK is an employee of Hoffman-La Roche Limited. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}